Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update

Gabriel Rinnerthaler; Christian Singer; Edgar Petru; Daniel Egle; Andreas Petzer; Ursula Pluschnig; Simon Peter Gampenrieder; Georg Pfeiler; Michael Gnant; Birgit Grünberger; Peter Krippl; Kathrin Strasser-Weippl; Christoph Suppan; Christine Brunner; Renate Pusch; Margit Sandholzer; Marija Balic; Rupert Bartsch

doi:10.1007/s00508-022-02082-3

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update

Wien Klin Wochenschr. 2022 Oct;134(19-20):683-692. doi: 10.1007/s00508-022-02082-3. Epub 2022 Sep 23.

Authors

Gabriel Rinnerthaler¹, Christian Singer², Edgar Petru³, Daniel Egle⁴, Andreas Petzer⁵, Ursula Pluschnig⁶, Simon Peter Gampenrieder¹, Georg Pfeiler², Michael Gnant⁷, Birgit Grünberger⁸, Peter Krippl⁹, Kathrin Strasser-Weippl¹⁰, Christoph Suppan¹¹, Christine Brunner⁴, Renate Pusch⁵, Margit Sandholzer¹², Marija Balic¹³, Rupert Bartsch¹⁴

Affiliations

¹ Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center, Paracelsus Medical University Salzburg, Müllner Hauptstr. 48, 5020, Salzburg, Austria.
² Department of Gynecology and Gynecological Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
³ Department of Gynecology and Obstetrics, Division of Gynecology, Medical University of Graz, Auenbruggerplatz 14, 8036, Graz, Austria.
⁴ Department of Gynecology, Breast Cancer Center Tirol, Medical University of Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria.
⁵ Barmherzige Schwestern, Elisabethinen, Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology, Ordensklinikum Linz GmbH, Seilerstätte 4, 4010, Linz, Austria.
⁶ Department of Internal Medicine and Hematology and Internal Oncology, Klagenfurt Hospital, Feschnigstr. 11, 9020, Klagenfurt am Wörthersee, Austria.
⁷ Comprehensive Cancer Center, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
⁸ Department of Internal Medicine and Hematology and Internal Oncology, Landesklinikum Wiener Neustadt, Corvinusring 3-5, 2700, Wiener Neustadt, Austria.
⁹ Department of Internal Medicine (location Fürstenfeld), Landeskrankenhaus Feldbach-Fürstenfeld, Krankenhausgasse 1, 8280, Fürstenfeld, Austria.
¹⁰ First Medical Department, Center for Oncology and Hematology, Klinik Ottakring, Montleartstr. 36, 1160, Vienna, Austria.
¹¹ Department of Internal Medicine, Division of Clinical Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria.
¹² Second Medical Department, Center for Oncology and Hematology, Landeskrankenhaus Feldkirch, Carinagasse 47, 6807, Feldkirch, Austria.
¹³ Department of Internal Medicine, Division of Clinical Oncology, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. marija.balic@medunigraz.at.
¹⁴ Department of Medicine I, Division of Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.

Abstract

In the past 12 months a plethora of relevant novel data for the treatment of metastatic HER2 positive breast cancer were published. To bring this new evidence into a clinical perspective, a group of Austrian breast cancer specialists updated their previously published treatment algorithm for those patients. For this consensus paper a total of eight scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.

Keywords: Advanced breast cancer; Antibody-drug conjugates; Erbb2; Systemic therapy; Tyrosin kinase inhibitors.

MeSH terms

Algorithms
Austria
Breast Neoplasms* / drug therapy
Breast Neoplasms* / pathology
Female
Humans
Neoplasms, Second Primary*
Receptor, ErbB-2 / therapeutic use

Substances

Receptor, ErbB-2